Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients.
Thirteen successfully transplanted renal patients with normal and elevated plasma lipids were treated as out-patients for two-month intervals with placebo and clofibrate (2 g/day) and whole plasma and lipoprotein triglyceride and cholesterol concentrations were measured. With clofibrate treatment, plasma triglyceride (194 +/- 11 to 157 +/- 10 mg/100 ml; P less than .01) and cholesterol (242 +/- 8 to 212 +/- 8 mg/100 ml; P less than .002) concentrations both decreased significantly despite the continued administration of stable immunosuppressive doses of prednisolone. While the absolute changes in cholesterol in the low and high-density lipoprotein classes varied considerably following clofibrate administration, the ratio of cholesterol in the low and high-density lipoproteins fell from 3.8 to 3.3. This theoretically beneficial anti-atherogenic effect was significant (P less than .01) in male allograft recipients only. These findings indicate that clofibrate treatment favorably influences the cardiovascular risk posed by both qualitative and quantitative disturbances in lipoprotein transport following successful renal allografting.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D010919:Placebos; D013997:Time Factors; D014184:Transplantation, Homologous; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate